James E. Butrynski

4.8k total citations · 1 hit paper
52 papers, 3.3k citations indexed

About

James E. Butrynski is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Gastroenterology. According to data from OpenAlex, James E. Butrynski has authored 52 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Pulmonary and Respiratory Medicine, 15 papers in Oncology and 14 papers in Gastroenterology. Recurrent topics in James E. Butrynski's work include Sarcoma Diagnosis and Treatment (28 papers), Gastrointestinal Tumor Research and Treatment (14 papers) and Vascular Tumors and Angiosarcomas (7 papers). James E. Butrynski is often cited by papers focused on Sarcoma Diagnosis and Treatment (28 papers), Gastrointestinal Tumor Research and Treatment (14 papers) and Vascular Tumors and Angiosarcomas (7 papers). James E. Butrynski collaborates with scholars based in United States, Hong Kong and Italy. James E. Butrynski's co-authors include George D. Demetri, Suzanne George, Nikhil H. Ramaiya, Andrew J. Wagner, Jeffrey A. Morgan, David R. D’Adamo, Jason L. Hornick, Geoffrey I. Shapiro, Keith D. Wilner and Pasi A. Jänne and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Biochemistry.

In The Last Decade

James E. Butrynski

50 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor

2010 604 citations James E. Butrynski, David R. D’Adamo et al. New England Journal of Medicine profile →

Peers

James E. Butrynski

PRM

ONCOL

RHEUM

GASTR

Adrián Mariño‐Enríquez United States

David R. D’Adamo United States

Philippe Terrier France

Dominique Ranchère‐Vince France

Mary Louise Keohan United States

W. Ruka Poland

Kristen N. Ganjoo United States

Binh Bui France

Beatrice Seddon United Kingdom

Mrinal M. Gounder United States

Adrián Mariño‐Enríquez United States

James E. Butrynski

2.2k ×1.1

PRM

861 ×0.7

ONCOL

1.1k ×1.5

RHEUM

734 ×1.1

434 ×0.7

GASTR

Citations per year, relative to James E. Butrynski James E. Butrynski (= 1×) peers Adrián Mariño‐Enríquez

Countries citing papers authored by James E. Butrynski

Since Specialization

Citations

This map shows the geographic impact of James E. Butrynski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James E. Butrynski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James E. Butrynski more than expected).

Fields of papers citing papers by James E. Butrynski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James E. Butrynski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James E. Butrynski. The network helps show where James E. Butrynski may publish in the future.

Co-authorship network of co-authors of James E. Butrynski

This figure shows the co-authorship network connecting the top 25 collaborators of James E. Butrynski. A scholar is included among the top collaborators of James E. Butrynski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James E. Butrynski. James E. Butrynski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Butrynski, James E., John C. Paschold, Patrick J. Ward, et al.. (2024). Biomarker testing in early-stage NSCLC: Results from the MYLUNG Consortium.. Journal of Clinical Oncology. 42(16_suppl). 8047–8047. 1 indexed citations

Corr, Bradley R., Ecaterina E. Dumbrava, Alexander I. Spira, et al.. (2024). 733P Efficacy and safety of sacituzumab govitecan (SG) in patients with advanced/metastatic endometrial cancer (EC): Updated results from TROPiCS-03. Annals of Oncology. 35. S558–S558. 1 indexed citations

Santin, Alessandro D., Bradley R. Corr, Alexander I. Spira, et al.. (2024). Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer. Journal of Clinical Oncology. 42(29). 3421–3429. 20 indexed citations

Taplin, Mary‐Ellen, Arif Hussain, Satish Shah, et al.. (2019). ProSTAR: A phase Ib/II study of CPI-1205, a small molecule inhibitor of EZH2, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 37(7_suppl). TPS335–TPS335. 12 indexed citations

Bui-Nguyen, B., James E. Butrynski, Nicolas Penel, et al.. (2015). A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: The TRUSTS trial. European Journal of Cancer. 51(10). 1312–1320. 59 indexed citations

Chawla, Sant P., Lee D. Cranmer, Brian A. Van Tine, et al.. (2014). Phase II Study of the Safety and Antitumor Activity of the Hypoxia-Activated Prodrug TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma. Journal of Clinical Oncology. 32(29). 3299–3306. 122 indexed citations

Choy, Edwin, James E. Butrynski, David C. Harmon, et al.. (2014). Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. BMC Cancer. 14(1). 813–813. 117 indexed citations

Ganjoo, Kristen N., Víctor M. Villalobos, Aya Kamaya, et al.. (2013). A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib. Annals of Oncology. 25(1). 236–240. 70 indexed citations

George, Suzanne, Qian Wang, Michael C. Heinrich, et al.. (2012). Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial. Journal of Clinical Oncology. 30(19). 2401–2407. 200 indexed citations

10.

Morgan, Elizabeth A., David Kozono, Qian Wang, et al.. (2012). Cutaneous Radiation-Associated Angiosarcoma of the Breast: Poor Prognosis in a Rare Secondary Malignancy. Annals of Surgical Oncology. 19(12). 3801–3808. 66 indexed citations

11.

Ganjoo, Kristen N., Lee D. Cranmer, James E. Butrynski, et al.. (2011). A Phase I Study of the Safety and Pharmacokinetics of the Hypoxia-Activated Prodrug TH-302 in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma. Oncology. 80(1-2). 50–56. 65 indexed citations

12.

Oliveira, Márcio Augusto de, Fabiana Martins, Qian Wang, et al.. (2011). Clinical presentation and management of mTOR inhibitor-associated stomatitis. Oral Oncology. 47(10). 998–1003. 84 indexed citations

13.

Vincenzi, Bruno, Daniele Santini, Gaia Schiavon, et al.. (2011). PML expression in soft tissue sarcoma: Prognostic and predictive value in alkylating agents/antracycline‐based first line therapy. Journal of Cellular Physiology. 227(4). 1657–1662. 3 indexed citations

14.

Sasaki, Takaaki, Katsuhiro Okuda, Wei Zheng, et al.. (2010). The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers. Cancer Research. 70(24). 10038–10043. 254 indexed citations

15.

Butrynski, James E., David R. D’Adamo, Jason L. Hornick, et al.. (2010). Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor. New England Journal of Medicine. 363(18). 1727–1733. 604 indexed citations breakdown →

16.

Long, Kevin B., et al.. (2010). Primary Extragastrointestinal Stromal Tumor of the Pleura: Report of a Unique Case With Genetic Confirmation. The American Journal of Surgical Pathology. 34(6). 907–912. 60 indexed citations

17.

Abraham, John A., Elizabeth H. Baldini, & James E. Butrynski. (2010). Management of adult soft-tissue sarcoma of the extremities and trunk. Expert Review of Anticancer Therapy. 10(2). 233–248. 4 indexed citations

18.

George, Suzanne, Priscilla Merriam, Robert G. Maki, et al.. (2009). Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor Sarcomas. Journal of Clinical Oncology. 27(19). 3154–3160. 249 indexed citations

19.

Hawkins, Douglas S., Ernest U. Conrad, James E. Butrynski, Scott M. Schuetze, & Janet F. Eary. (2009). [F‐18]‐fluorodeoxy‐D‐glucose–positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults. Cancer. 115(15). 3519–3525. 83 indexed citations

20.

Raut, Chandrajit P., Qian Wang, Judith Manola, et al.. (2009). Cytoreductive Surgery in Patients with Metastatic Gastrointestinal Stromal Tumor Treated with Sunitinib Malate. Annals of Surgical Oncology. 17(2). 407–415. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact